UNC Lineberger Comprehensive Cancer Center researchers will share their expertise and research findings at the American Society of Clinical Oncology annual meeting, which is expected to draw thousands of oncology professionals from around the world to Chicago Friday through June 2.
UNC Lineberger members were authors on nearly 30 abstracts that will be presented at the meeting. Their studies include early findings from a trial testing a specific chemotherapy combination in people with head and neck cancer to an investigation into the impact of race and insurance status on prostate cancer treatment.
Early findings from abstracts that will be presented at the meeting include:
Chemotherapy improves access to breast conservation surgery, but many women still choose mastectomy
With new drug combinations, UNC Lineberger researchers and partners have found in a new study that they could improve the rates of patients with two different types of breast cancer who are eligible for breast conservation surgery. Yet, they also found that a substantial number of women still chose mastectomy.
Building off of a similar study that evaluated the impact of drug combinations in women with triple-negative breast cancer, the study led by Mehra Golshan, MD, director of Breast Surgical Services at Dana-Farber/Brigham and Women’s Cancer Center, looked at the impact of treatment combinations in women with triple-negative and HER2-positive breast cancer. Golshan is also director of Breast Surgical Services at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute
“With this research, we’ve shown that we can offer breast-conserving therapy to more women in both triple-negative and in HER2-positive breast cancer,” said David Ollila, MD, the James and Jesse Millis Distinguished Professor of Surgery at the UNC School of Medicine, co-director of the UNC Breast Program, a UNC Lineberger member and the study's senior author. “The surgery is successful in most women who choose it. Yet, this study also shows that a significant number of women continue to choose mastectomy.”
The preliminary findings will be presented in an oral abstract session that will be held from 3 to 6 p.m. Monday, June 1. More information.
With lower intensity chemoradiotherapy, most cancer free in HPV-positive oropharyngeal cancer subgroup
UNC Lineberger researchers are releasing preliminary results of a new study evaluating whether lower doses of radiation and chemotherapy treatments can be given successfully to a subgroup of patients with oropharyngeal cancer of the tonsil and base of tongue. The study builds on previous research that’s shown that oropharyngeal cancer patients who test positively for human papillomavirus (HPV) have higher response rates to radiation and chemotherapy, excellent cancer control rates, and better overall survival than patients whose cancer is HPV-negative.
For the study, 43 patients were included who had favorable-risk, HPV-or-p16-positive oropharyngeal squamous cell carcinomas.
“This study shows really promising preliminary data that suggests that we are probably over-treating these patients with the standard radiation and chemotherapy regimens,” said Bhishamjit S. Chera, MD, a UNC Lineberger member, an assistant professor in the UNC School of Medicine Department of Radiation Oncology and the study’s first author and principal investigator. “We have shown that we may be able to safely lower the radiation and chemotherapy doses, while still maintaining excellent cancer control, and at the same time, reducing toxicity.”
The abstract will be presented at ASCO’s annual meeting during a Monday, June 1, session at 2:30 p.m. More information.
Study looks at disparities in prostate cancer treatments based on race, insurance status
A UNC Lineberger-led study compared the level of prostate cancer treatment for thousands of men in the United States to investigate whether they were treated less aggressively and received less advanced treatment based on their race or insurance status.
The study, whose senior author was Ronald Chen, MD, MPH, a UNC Lineberger member and an associate professor in the UNC School of Medicine Department of Radiation Oncology, analyzed National Cancer Data Base data for 12,778 men aged less than age 65 years.
The early findings will be presented in a poster session from 1:15 to 4:45 p.m. Monday, June 1. More information.
UNC researchers will also be presenting and speaking at the following times:
Friday, May 29 - View full day's agenda
- Federico Innocenti, 3:05- 3:25 pm: Meet-the-Professor Session: Pharmacogenomics to Predict Cancer Outcomes and Responses to Anticancer Therapies
- David N. Hayes, 4:05 - 4:25 pm: Education Session: Expediting the Learning Curve for Applied Cancer Genomics. Presentation: Clinical-Grade Deep Sequencing for Cancer
- Hyman B. Muss, 4:50- 5:10 pm: Education Session: Individualizing the Approach to the Older Woman with Breast Cancer. Presentation: Chemotherapy for Older Patients with Breast Cancer: Should We Use More or Less?
Saturday, May 30 - View full day's agenda
8:00 - 11:30 am: Poster Session - Breast Cancer-Triple-Negative/Cytotoxics/Local Therapy
- Elizabeth Claire Dees: Phase I dose-finding study of the gamma secretase inhibitor PF-03084014 (PF-4014) in combination with docetaxel in patients (pts) with advanced triple-negative breast cancer (TNBC)
- Tomohiro Funakoshi: A comparison of toxicity profiles between standard and lower dose capecitabine (CAP) in breast cancer (BC): a meta-analysis
- Jahan J. Mohiuddin: Utilization of neoadjuvant systemic therapy (NST) for breast cancer
- Hyman B. Muss: Standard chemotherapy versus capcitabine for older women with early stage breast cancer: An update of CALGB/CTSU/Alliance 49907
- Joel S. Parker: A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC
8:00 - 11:30 am: Poster Session – Developmental Therapeutics – Immunotherapy
- Alisha Holtzhausen: Targeting the Wnt5a-β-catenin pathway in the melanoma microenvironment to augment checkpoint inhibitor immunotherapy
- Hyman Muss, 10:20 - 10:45 am: Extended Education Session Panel Moderator: Digital Geriatric Oncology in Research and Practice—How to Get the Right Data in and Out
1:15 - 4:45 pm – Poster Session- Patient and Survivor Care
- Aaron Falchook: Use of mobile device technology to collect patient-reported symptoms during radiotherapy for head and neck cancer: A prospective feasibility study
- Emily Guerard: Construction of a frailty index for older adults with cancer using a geriatric assessment
- Deborah Mayer: Using survivorship care plans (SCP) to improve cancer communication and care coordination
- Kirsten Nyrop: Feasibility of a home-based walking program in female breast cancer patients age 60+ during chemotherapy
- Mackenzi Pergolotti: Health related quality of life (HRQOL) in older adults with cancer: The potential of a single-item screen
1:15 - 4:45 p.m. Poster Session – Head and Neck Cancer
- Jared Weiss: Response rates, toxicity, and quality of life for locally regionally advanced head and neck squamous cell carcinoma after induction chemotherapy with weekly nab-paclitaxel, carboplatin, and cetuximab
- Jared Weiss: Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients
1:15 - 4:15 p.m. Oral Abstract Session - Leukemia, Myelodysplasia, and Transplantation
- Joshua Zeidner: Correlation of acute myeloid leukemia (AML) stem cell phenotype with cytogenetic/molecular features and prognosis
- Hanna Sanoff, 1:35 - 1:55 pm: Education session -- Adjuvant Therapy for Stage II and III Colon Cancer: Patient Selection, Optimal Agents, and Chemoprevention. Chemotherapy for Stage III
- Charles M. Perou, 1:15- 1:35 pm: What Can I Learn about My Tumor by Looking at Yours? The PAN-CAN Project. Education session: How to Translate the Wealth of Information in the Cancer Genome Atlas into Improved Outcomes: Data Mining and Biologic Validation
- Anne-Marie Meyer, 5:25 - 5:45 pm: Education Session - The Learning Health Care System: Using Big Data to Inform Clinical Decision-Making. “Big Data in Practice: Practical Tips for Using Big Data in Cancer Care.”
- Frances A. Collichio, 4:45 - 5:05 pm: Presentation: “Immune-Related Adverse Events Associated with CTLA4 and PD1/PDL1 Blockade." Clinical Problems in Oncology Session - Immunotherapy for Melanoma: Sequencing, Combinations, and Side Effects.
Monday, June 1 - View full day's agenda
8:00 - 11:30 am: Poster Session- Gastrointestinal (Colorectal) Cancer
- Federico Innocenti: A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405
- Andrew Wang: Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer
- Grant Williams: Genotype-directed phase II study of irinotecan dosing in metastatic colorectal cancer (mCRC) patients receiving FOLFIRI + bevacizumab: The GENIC study
8:00 - 11:30 am: Poster Session - Gastrointestinal (Noncolorectal) Cancer
- Robert Torphy: Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma. Poster Discussion Session
8 - 11:30 am: Poster Session – Lung Cancer – Non-Small Cell Metastatic
- Jared Weiss: Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC
1:15 - 4:45 pm: Poster Session - Health Services Research and Quality of Care
- Stephanie B. Wheeler: Endocrine therapy adherence, side effects, and risk perception among racially diverse breast cancer patients
1:15 - 4:45 pm: Poster Session - Central Nervous System Tumors
3:00 - 6:00 pm: Oral Abstract Session - Tumor Biology
- Carrie B. Lee: Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors
Tuesday, June 2 - View full day's agenda
Deborah Mayer, 10:05 - 10:25 am: Integration of Survivorship Care Plans into Electronic Health Records.” Education session: Moving Survivorship Care Forward: Lessons from Quality Measures